



Teleflex Receives FDA Clearance for ARROW-Clark™ VectorFlow™ Chronic Hemodialysis Catheter

July 22, 2014

WAYNE, Pa.--(BUSINESS WIRE)--Jul. 22, 2014-- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical devices for critical care and surgery, has announced it has received FDA 510(k) clearance to market its ARROW-Clark™ VectorFlow™ Chronic Hemodialysis Catheter. Designed by Dr. Timothy Clark, M.D., the VectorFlow™ Catheter features a symmetrical tip design that allows ease of placement and sustained high flows with minimal recirculation.

“Providing clinicians with the ARROW-Clark™ VectorFlow™ Catheter continues a series of new product introductions that demonstrates our commitment to enhance patient outcomes and improve ease of use for clinicians,” said Linda Beneze, President and General Manager, Specialty Division. “We are proud to add the VectorFlow™ Catheter to our portfolio.”

The ARROW-Clark™ VectorFlow™ Catheter is the only catheter with an innovative tip designed to produce a helical, three-dimensional transition of blood entering and leaving the catheter.¹

About Teleflex Incorporated

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Wayne, PA, Teleflex employs approximately 11,400 people worldwide and serves healthcare providers in more than 150 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, Arrow, ARROW-Clark and VectorFlow are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.

© 2014 Teleflex Incorporated. All rights reserved. MC-000213

References:

1. Clark T, et al. Computational Flow Dynamics and Preclinical Assessment of a Novel Hemodialysis Catheter. *Seminars in Dialysis*. 2012.

Source: Teleflex Incorporated

Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610-948-2836
jake.elguicze@teleflex.com
www.teleflex.com